{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:58:58Z","timestamp":1792198738189,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The progressive consumption growth of non-steroidal anti-inflammatory drugs (NSAIDs) has progressively raised the attention toward the gastrointestinal, renal, and cardiovascular toxicity. Increased risk of cardiovascular diseases was strictly associated with the usage of COX-2 selective NSAIDs. Other studies allowed to clarify that the cardiovascular risk is not limited to COX-2 selective but also extended to non-selective NSAIDs, such as Diclofenac and Ketoprofen. To date, although a less favorable cardiovascular risk profile for Diclofenac as compared to Ketoprofen is reported, the mechanisms through which NSAIDs cause adverse cardiovascular events are not entirely understood. The present study aimed to evaluate the effects of Ketoprofen in comparison with Diclofenac in immortalized human cardiomyocytes. The results obtained highlight the dose-dependent cardiotoxicity of Diclofenac compared to Ketoprofen. Despite both drugs induce the increase in ROS production, decrease of mitochondrial membrane potential, and proteasome activity modulation, only Diclofenac exposure shows a marked alteration of these intracellular parameters, leading to cell death. Noteworthy, Diclofenac decreases the proteasome 26S DC and this scenario may be dependent on the intracellular overload of oxidized proteins. The data support the hypothesis that immortalized human cardiomyocytes exposed to Ketoprofen are subjected to tolerable stress events, conversely Diclofenac exposition triggers cell death.<\/jats:p>","DOI":"10.1038\/s41598-020-75394-x","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T11:03:40Z","timestamp":1603796620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["NSAIDs-dependent adaption of the mitochondria-proteasome system in immortalized human cardiomyocytes"],"prefix":"10.1038","volume":"10","author":[{"given":"Laura","family":"Brandolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antonosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"d\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"75394_CR1","unstructured":"Peterson, K. et al. Drug class review nonsteroidal antiinflammatory drugs (NSAIDs). Update (2006)."},{"key":"75394_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00003495-200363060-00001","volume":"63","author":"GS Bleumink","year":"2003","unstructured":"Bleumink, G. S., Feenstra, J., Sturkenboom, M. C. J. M. & Stricker, B. H. C. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63, 525\u2013534 (2003).","journal-title":"Drugs"},{"key":"75394_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1098-3597(01)90069-9","volume":"3","author":"GA Green","year":"2001","unstructured":"Green, G. A. Understanding NSAIDs: From aspirin to COX-2. Clin. Cornerstone 3, 50\u201360 (2001).","journal-title":"Clin. Cornerstone"},{"key":"75394_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232\u2013235 (1971).","journal-title":"Nat. New Biol."},{"key":"75394_CR5","first-page":"275","volume":"6","author":"G Weissmann","year":"1993","unstructured":"Weissmann, G. Prostaglandins as modulators rather than mediators of inflammation. J. Lipid Mediat. 6, 275\u2013286 (1993).","journal-title":"J. Lipid Mediat."},{"key":"75394_CR6","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","volume":"90","author":"JA Mitchell","year":"1993","unstructured":"Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J. & Vane, J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90, 11693\u201311697 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75394_CR7","doi-asserted-by":"publisher","first-page":"11202","DOI":"10.1073\/pnas.91.23.11202","volume":"91","author":"RA Copeland","year":"1994","unstructured":"Copeland, R. A. et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G\/H synthase. Proc. Natl. Acad. Sci. USA 91, 11202\u201311206 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75394_CR8","doi-asserted-by":"publisher","first-page":"40S","DOI":"10.1016\/0002-9343(93)90396-7","volume":"95","author":"DL DeWitt","year":"1993","unstructured":"DeWitt, D. L., Meade, E. A. & Smith, W. L. PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs. Am. J. Med. 95, 40S-44S (1993).","journal-title":"Am. J. Med."},{"key":"75394_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0140-6736(99)12031-2","volume":"355","author":"DA Willoughby","year":"2000","unstructured":"Willoughby, D. A., Moore, A. R. & Colville-Nash, P. R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet (London, England) 355, 646\u2013648 (2000).","journal-title":"Lancet (London, England)"},{"key":"75394_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/089771502753754091","volume":"19","author":"KI Strauss","year":"2002","unstructured":"Strauss, K. I. & Marini, A. M. Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J. Neurotrauma 19, 627\u2013638 (2002).","journal-title":"J. Neurotrauma"},{"key":"75394_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/1-4020-5688-5_5","volume":"42","author":"L Minghetti","year":"2007","unstructured":"Minghetti, L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell. Biochem. 42, 127\u2013141 (2007).","journal-title":"Subcell. Biochem."},{"key":"75394_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520\u20131528 (2000) (2 p following 1528).","journal-title":"N. Engl. J. Med."},{"key":"75394_CR13","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1161\/01.CIR.0000132491.96623.04","volume":"109","author":"LA Garc\u00eda Rodr\u00edguez","year":"2004","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., Varas-Lorenzo, C., Maguire, A. & Gonz\u00e1lez-P\u00e9rez, A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109, 3000\u20133006 (2004).","journal-title":"Circulation"},{"key":"75394_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0140-6736(08)60137-3","volume":"371","author":"TD Warner","year":"2008","unstructured":"Warner, T. D. & Mitchell, J. A. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (London, England) 371, 270\u2013273 (2008).","journal-title":"Lancet (London, England)"},{"key":"75394_CR15","doi-asserted-by":"publisher","first-page":"17017","DOI":"10.1073\/pnas.1011278107","volume":"107","author":"J-Y Liu","year":"2010","unstructured":"Liu, J.-Y. et al. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc. Natl. Acad. Sci. USA 107, 17017\u201317022 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75394_CR16","first-page":"1144","volume":"9","author":"Z Varga","year":"2017","unstructured":"Varga, Z., Sabzwari, S. R. A. & Vargova, V. cardiovascular risk of nonsteroidal anti-inflammatory drugs: An under-recognized public health issue. Cureus 9, 1144 (2017).","journal-title":"Cureus"},{"key":"75394_CR17","unstructured":"EMA\/696137\/2012. Assessment Report for Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Cardiovascular Risk. EMA\/696137\/2012."},{"key":"75394_CR18","doi-asserted-by":"publisher","first-page":"i4857","DOI":"10.1136\/bmj.i4857","volume":"354","author":"A Arf\u00e8","year":"2016","unstructured":"Arf\u00e8, A. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: Nested case\u2013control study. BMJ 354, i4857 (2016).","journal-title":"BMJ"},{"key":"75394_CR19","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1074\/jbc.M708100200","volume":"283","author":"RV Frolov","year":"2008","unstructured":"Frolov, R. V., Berim, I. G. & Singh, S. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: A novel effect of celecoxib and the mechanism underlying it. J. Biol. Chem. 283, 1518\u20131524 (2008).","journal-title":"J. Biol. Chem."},{"key":"75394_CR20","doi-asserted-by":"publisher","DOI":"10.13140\/2.1.3971.2320","volume-title":"Sudden Cardiac Death: Epidemiology, Genetics and Predictive\/Prevention Strategies","author":"SM Hwang","year":"2013","unstructured":"Hwang, S. M., Gilda, J. E., Cui, Z. & Gomes, A. V. Non-steroidal anti-inflammatory drugs and increased risk of sudden cardiac death. In Sudden Cardiac Death: Epidemiology, Genetics and Predictive\/Prevention Strategies (ed. Santangeli, P.) (Nova Science Publishers, New York, 2013). https:\/\/doi.org\/10.13140\/2.1.3971.2320."},{"key":"75394_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/jid.2011.316","volume":"132","author":"FK Braun","year":"2012","unstructured":"Braun, F. K. et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J. Invest. Dermatol. 132, 429\u2013439 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"75394_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/carcin\/23.1.107","volume":"23","author":"G Hawcroft","year":"2002","unstructured":"Hawcroft, G. et al. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 23, 107\u2013114 (2002).","journal-title":"Carcinogenesis"},{"key":"75394_CR23","first-page":"2452","volume":"57","author":"GA Piazza","year":"1997","unstructured":"Piazza, G. A. et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57, 2452\u20132459 (1997).","journal-title":"Cancer Res."},{"key":"75394_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/excr.1996.0023","volume":"222","author":"SJ Shiff","year":"1996","unstructured":"Shiff, S. J., Koutsos, M. I., Qiao, L. & Rigas, B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp. Cell Res. 222, 179\u2013188 (1996).","journal-title":"Exp. Cell Res."},{"key":"75394_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI118060","volume":"96","author":"SJ Shiff","year":"1995","unstructured":"Shiff, S. J., Qiao, L., Tsai, L. L. & Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96, 491\u2013503 (1995).","journal-title":"J. Clin. Invest."},{"key":"75394_CR26","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/carcin\/22.9.1393","volume":"22","author":"XM Zhou","year":"2001","unstructured":"Zhou, X. M. et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 22, 1393\u20131397 (2001).","journal-title":"Carcinogenesis"},{"key":"75394_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.neo.7900120","volume":"2","author":"KC Zimmermann","year":"2000","unstructured":"Zimmermann, K. C., Waterhouse, N. J., Goldstein, J. C., Schuler, M. & Green, D. R. Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia 2, 505\u2013513 (2000).","journal-title":"Neoplasia"},{"key":"75394_CR28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-03-2396","volume":"64","author":"SK Kulp","year":"2004","unstructured":"Kulp, S. K. et al. 3-Phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64, 1444\u20131451 (2004).","journal-title":"Cancer Res."},{"key":"75394_CR29","doi-asserted-by":"publisher","first-page":"26900","DOI":"10.1074\/jbc.273.41.26900","volume":"273","author":"S Simizu","year":"1998","unstructured":"Simizu, S., Takada, M., Umezawa, K. & Imoto, M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J. Biol. Chem. 273, 26900\u201326907 (1998).","journal-title":"J. Biol. Chem."},{"key":"75394_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/0006-2952(95)00233-P","volume":"50","author":"S Verhaegen","year":"1995","unstructured":"Verhaegen, S., McGowan, A. J., Brophy, A. R., Fernandes, R. S. & Cotter, T. G. Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Biochem. Pharmacol. 50, 1021\u20131029 (1995).","journal-title":"Biochem. Pharmacol."},{"key":"75394_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0014-2999(99)00599-3","volume":"383","author":"H Kusuhara","year":"1999","unstructured":"Kusuhara, H., Komatsu, H., Sumichika, H. & Sugahara, K. Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. Eur. J. Pharmacol. 383, 331\u2013337 (1999).","journal-title":"Eur. J. Pharmacol."},{"key":"75394_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/B978-0-12-369521-5.00013-0","volume":"73","author":"M Hacker","year":"2009","unstructured":"Hacker, M. Adverse drug reactions. Pharmacology 73, 327\u2013352 (2009).","journal-title":"Pharmacology"},{"key":"75394_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yjmcc.2016.03.016","volume":"94","author":"R Ghosh","year":"2016","unstructured":"Ghosh, R., Hwang, S. M., Cui, Z., Gilda, J. E. & Gomes, A. V. Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells. J. Mol. Cell. Cardiol. 94, 131\u2013144 (2016).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"75394_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cardiores.2005.04.012","volume":"67","author":"VPM van Empel","year":"2005","unstructured":"van Empel, V. P. M. et al. Myocyte apoptosis in heart failure. Cardiovasc. Res. 67, 21\u201329 (2005).","journal-title":"Cardiovasc. Res."},{"key":"75394_CR35","doi-asserted-by":"publisher","first-page":"29228","DOI":"10.1074\/jbc.M602629200","volume":"281","author":"P Dikshit","year":"2006","unstructured":"Dikshit, P., Chatterjee, M., Goswami, A., Mishra, A. & Jana, N. R. Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem. 281, 29228\u201329235 (2006).","journal-title":"J. Biol. Chem."},{"key":"75394_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbagrm.2010.09.001","volume":"1809","author":"Y-F Li","year":"2011","unstructured":"Li, Y.-F. & Wang, X. The role of the proteasome in heart disease. Biochim. Biophys. Acta 1809, 141\u2013149 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"75394_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/cvr\/cvp287","volume":"85","author":"H Su","year":"2010","unstructured":"Su, H. & Wang, X. The ubiquitin-proteasome system in cardiac proteinopathy: A quality control perspective. Cardiovasc. Res. 85, 253\u2013262 (2010).","journal-title":"Cardiovasc. Res."},{"key":"75394_CR38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ijcard.2016.08.233","volume":"223","author":"R Ghosh","year":"2016","unstructured":"Ghosh, R., Goswami, S. K., Feitoza, L. F. B. B., Hammock, B. & Gomes, A. V. Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts. Int. J. Cardiol. 223, 923\u2013935 (2016).","journal-title":"Int. J. Cardiol."},{"key":"75394_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.yjmcc.2005.03.003","volume":"39","author":"MM Davidson","year":"2005","unstructured":"Davidson, M. M. et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39, 133\u2013147 (2005).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"75394_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0008-6363(01)00324-8","volume":"51","author":"AA van Veen","year":"2001","unstructured":"van Veen, A. A., van Rijen, H. V. & Opthof, T. Cardiac gap junction channels: Modulation of expression and channel properties. Cardiovasc. Res. 51, 217\u2013229 (2001).","journal-title":"Cardiovasc. Res."},{"key":"75394_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/j.1460-2075.1996.tb00361.x","volume":"15","author":"T Braun","year":"1996","unstructured":"Braun, T. & Arnold, H. H. Myf-5 and myoD genes are activated in distinct mesenchymal stem cells and determine different skeletal muscle cell lineages. EMBO J. 15, 310\u2013318 (1996).","journal-title":"EMBO J."},{"key":"75394_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diff.2016.02.005","volume":"92","author":"SG Almalki","year":"2017","unstructured":"Almalki, S. G. & Agrawal, D. K. Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation 92, 41\u201351 (2017).","journal-title":"Differentiation"},{"key":"75394_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.21769\/BioProtoc.3128","volume":"9","author":"F Sivandzade","year":"2019","unstructured":"Sivandzade, F., Bhalerao, A. & Cucullo, L. Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe. Bio-Protocol 9, 139\u2013148 (2019).","journal-title":"Bio-Protocol"},{"key":"75394_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-6346-1_2","volume":"1473","author":"S Sakamuru","year":"2016","unstructured":"Sakamuru, S., Attene-Ramos, M. S. & Xia, M. Mitochondrial membrane potential assay. Methods Mol. Biol. 1473, 17\u201322 (2016).","journal-title":"Methods Mol. Biol."},{"key":"75394_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2144\/000113610","volume":"50","author":"SW Perry","year":"2011","unstructured":"Perry, S. W., Norman, J. P., Barbieri, J., Brown, E. B. & Gelbard, H. A. Mitochondrial membrane potential probes and the proton gradient: A practical usage guide. Biotechniques 50, 98\u2013115 (2011).","journal-title":"Biotechniques"},{"key":"75394_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF01868640","volume":"115","author":"J Gutknecht","year":"1990","unstructured":"Gutknecht, J. Salicylates and proton transport through lipid bilayer membranes: A model for salicylate-induced uncoupling and swelling in mitochondria. J. Membr. Biol. 115, 253\u2013260 (1990).","journal-title":"J. Membr. Biol."},{"key":"75394_CR47","doi-asserted-by":"publisher","first-page":"16186","DOI":"10.1074\/jbc.M110.198952","volume":"286","author":"E Mu\u00f1oz","year":"2011","unstructured":"Mu\u00f1oz, E. et al. Nonsteroidal anti-inflammatory drugs inhibit vascular smooth muscle cell proliferation by enabling the Ca2+-dependent inactivation of calcium release-activated calcium\/orai channels normally prevented by mitochondria. J. Biol. Chem. 286, 16186\u201316196 (2011).","journal-title":"J. Biol. Chem."},{"key":"75394_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1113\/jphysiol.2005.100586","volume":"571","author":"L N\u00fa\u00f1ez","year":"2006","unstructured":"N\u00fa\u00f1ez, L. et al. Cell proliferation depends on mitochondrial Ca2+ uptake: Inhibition by salicylate. J. Physiol. 571, 57\u201373 (2006).","journal-title":"J. Physiol."},{"key":"75394_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/jhep.2002.31871","volume":"35","author":"Y Masubuchi","year":"2002","unstructured":"Masubuchi, Y., Nakayama, S. & Horie, T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35, 544\u2013551 (2002).","journal-title":"Hepatology"},{"key":"75394_CR50","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","volume":"97","author":"B Halliwell","year":"2006","unstructured":"Halliwell, B. Oxidative stress and neurodegeneration: Where are we now?. J. Neurochem. 97, 1634\u20131658 (2006).","journal-title":"J. Neurochem."},{"key":"75394_CR51","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nature02263","volume":"426","author":"AL Goldberg","year":"2003","unstructured":"Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895\u2013899 (2003).","journal-title":"Nature"},{"key":"75394_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ab.2013.10.018","volume":"446","author":"Z Cui","year":"2014","unstructured":"Cui, Z., Gilda, J. E. & Gomes, A. V. Crude and purified proteasome activity assays are affected by type of microplate. Anal. Biochem. 446, 44\u201352 (2014).","journal-title":"Anal. Biochem."},{"key":"75394_CR53","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.leukres.2010.07.003","volume":"34","author":"A Liggett","year":"2010","unstructured":"Liggett, A., Crawford, L. J., Walker, B., Morris, T. C. M. & Irvine, A. E. Methods for measuring proteasome activity: Current limitations and future developments. Leuk. Res. 34, 1403\u20131409 (2010).","journal-title":"Leuk. Res."},{"key":"75394_CR54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0076-6879(05)98030-0","volume":"398","author":"AF Kisselev","year":"2005","unstructured":"Kisselev, A. F. & Goldberg, A. L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398, 364\u2013378 (2005).","journal-title":"Methods Enzymol."},{"key":"75394_CR55","doi-asserted-by":"publisher","first-page":"R110.006924","DOI":"10.1074\/mcp.M110.006924","volume":"10","author":"CT Aiken","year":"2011","unstructured":"Aiken, C. T., Kaake, R. M., Wang, X. & Huang, L. Oxidative stress-mediated regulation of proteasome complexes. Mol. Cell. Proteomics 10, R110.006924 (2011).","journal-title":"Mol. Cell. Proteomics"},{"issue":"Pt 3","key":"75394_CR56","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1042\/bj3350637","volume":"335","author":"T Reinheckel","year":"1998","unstructured":"Reinheckel, T. et al. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem. J. 335(Pt 3), 637\u2013642 (1998).","journal-title":"Biochem. J."},{"key":"75394_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mam.2016.05.001","volume":"50","author":"R Raynes","year":"2016","unstructured":"Raynes, R., Pomatto, L. C. D. & Davies, K. J. A. Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. Mol. Asp. Med. 50, 41\u201355 (2016).","journal-title":"Mol. Asp. Med."},{"key":"75394_CR58","first-page":"ra88","volume":"3","author":"X Wang","year":"2010","unstructured":"Wang, X., Yen, J., Kaiser, P. & Huang, L. Regulation of the 26S proteasome complex during oxidative stress. Sci. Signal. 3, ra88 (2010).","journal-title":"Sci. Signal."},{"key":"75394_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/CRD.0b013e3181ce1521","volume":"18","author":"M Amer","year":"2010","unstructured":"Amer, M., Bead, V. R., Bathon, J., Blumenthal, R. S. & Edwards, D. N. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease. Cardiol. Rev. 18, 204\u2013212 (2010).","journal-title":"Cardiol. Rev."},{"key":"75394_CR60","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092\u20131102 (2005).","journal-title":"N. Engl. J. Med."},{"key":"75394_CR61","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071\u20131080 (2005).","journal-title":"N. Engl. J. Med."},{"key":"75394_CR62","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney, P. M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302\u20131308 (2006).","journal-title":"BMJ"},{"key":"75394_CR63","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","volume":"52","author":"LA Garc\u00eda Rodr\u00edguez","year":"2008","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., Tacconelli, S. & Patrignani, P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52, 1628\u20131636 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"75394_CR64","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan, P. & Henry, D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 8, e1001098 (2011).","journal-title":"PLoS Med."},{"key":"75394_CR65","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ 342, c7086\u2013c7086 (2011).","journal-title":"BMJ"},{"key":"75394_CR66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Coxib and Traditional NSAID Trialists\u2019 (CNT) Collaboration","year":"2013","unstructured":"Coxib and Traditional NSAID Trialists\u2019 (CNT) Collaboration et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet (London, England) 382, 769\u2013779 (2013).","journal-title":"Lancet (London, England)"},{"key":"75394_CR67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/1759720X14541668","volume":"6","author":"J Fabule","year":"2014","unstructured":"Fabule, J. & Adebajo, A. Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs. Ther. Adv. Musculoskelet. Dis. 6, 111\u2013130 (2014).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"75394_CR68","doi-asserted-by":"publisher","first-page":"e1001388","DOI":"10.1371\/journal.pmed.1001388","volume":"10","author":"P McGettigan","year":"2013","unstructured":"McGettigan, P. & Henry, D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: An examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 10, e1001388 (2013).","journal-title":"PLoS Med."},{"key":"75394_CR69","first-page":"229","volume":"248","author":"B Escalante","year":"1989","unstructured":"Escalante, B., Sessa, W. C., Falck, J. R., Yadagiri, P. & Schwartzman, M. L. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J. Pharmacol. Exp. Ther. 248, 229\u2013232 (1989).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"75394_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10555-011-9301-4","volume":"30","author":"X Wang","year":"2011","unstructured":"Wang, X., Baek, S. J. & Eling, T. COX inhibitors directly alter gene expression: Role in cancer prevention?. Cancer Metastasis Rev. 30, 641\u2013657 (2011).","journal-title":"Cancer Metastasis Rev."},{"key":"75394_CR71","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1054\/bjoc.2000.1143","volume":"82","author":"Y Chen","year":"2000","unstructured":"Chen, Y. & Hughes-Fulford, M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br. J. Cancer 82, 2000\u20132006 (2000).","journal-title":"Br. J. Cancer"},{"key":"75394_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1124\/pr.54.1.101","volume":"54","author":"A Szewczyk","year":"2002","unstructured":"Szewczyk, A. & Wojtczak, L. Mitochondria as a pharmacological target. Pharmacol. Rev. 54, 101\u2013127 (2002).","journal-title":"Pharmacol. Rev."},{"key":"75394_CR73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.yjmcc.2019.02.006","volume":"129","author":"DN Meijles","year":"2019","unstructured":"Meijles, D. N. et al. The cardiomyocyte \u2018redox rheostat\u2019: Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death. J. Mol. Cell. Cardiol. 129, 118\u2013129 (2019).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"75394_CR74","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/abbi.1997.9985","volume":"342","author":"SA Uyemura","year":"1997","unstructured":"Uyemura, S. A., Santos, A. C., Mingatto, F. E., Jordani, M. C. & Curti, C. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. 342, 231\u2013235 (1997).","journal-title":"Arch. Biochem. Biophys."},{"key":"75394_CR75","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/HCO.0b013e32834598fe","volume":"26","author":"S Schlossarek","year":"2011","unstructured":"Schlossarek, S. & Carrier, L. The ubiquitin-proteasome system in cardiomyopathies. Curr. Opin. Cardiol. 26, 190\u2013195 (2011).","journal-title":"Curr. Opin. Cardiol."},{"key":"75394_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10974-011-9273-6","volume":"33","author":"S Schlossarek","year":"2012","unstructured":"Schlossarek, S. et al. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice. J. Muscle Res. Cell Motil. 33, 5\u201315 (2012).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"75394_CR77","doi-asserted-by":"publisher","first-page":"C793","DOI":"10.1152\/ajpcell.00198.2016","volume":"311","author":"T Mayor","year":"2016","unstructured":"Mayor, T., Sharon, M. & Glickman, M. H. Tuning the proteasome to brighten the end of the journey. Am. J. Physiol. Cell Physiol. 311, C793\u2013C804 (2016).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"75394_CR78","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.18632\/aging.102733","volume":"12","author":"A Antonosante","year":"2020","unstructured":"Antonosante, A. et al. Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics. Aging (Albany, NY) 12, 1928\u20131951 (2020).","journal-title":"Aging (Albany, NY)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75394-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75394-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75394-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:15:10Z","timestamp":1670364910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75394-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75394-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laura Brandolini, Cristina Giorgio, Michela Bagnasco, and Marcello Allegretti are employees of Domp\u00e9 Farmaceutici SpA, Italy. The company has interests in the development of NSAIDs for the treatment of inflammatory diseases. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18337"}}